• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Plasma tissue factor pathway inhibitor levels in angiographically defined coronary artery disease among saudis.沙特人群中血管造影确诊的冠状动脉疾病患者的血浆组织因子途径抑制物水平
Oman Med J. 2013 May;28(3):191-4. doi: 10.5001/omj.2013.52.
2
Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI.肢端肥大症患者的血液凝固与纤维蛋白溶解:纤溶酶原激活物抑制剂-1(PAI-1)增加,组织因子途径抑制剂(TFPI)减少,且生长激素与TFPI呈负相关。
Endocrine. 2008 Jun;33(3):270-6. doi: 10.1007/s12020-008-9088-4.
3
Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.原发性甲状旁腺功能亢进患者血浆纤溶酶原激活物抑制剂-1水平升高、组织因子途径抑制剂水平降低,而凝血酶激活的纤维蛋白溶解抑制剂水平无变化。
Eur J Endocrinol. 2009 May;160(5):863-8. doi: 10.1530/EJE-09-0069. Epub 2009 Feb 20.
4
Relationship of high sensitivity C-reactive protein with presence and severity of coronary artery disease.高敏 C 反应蛋白与冠状动脉疾病的存在及严重程度的关系。
Pak J Med Sci. 2013 Nov;29(6):1425-9. doi: 10.12669/pjms.296.3302.
5
Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.库欣综合征患者的血液凝固与纤维蛋白溶解:纤溶酶原激活物抑制剂-1升高、组织因子途径抑制剂降低,凝血酶激活的纤维蛋白溶解抑制剂水平无变化。
J Endocrinol Invest. 2009 Feb;32(2):169-74. doi: 10.1007/BF03345709.
6
The relationship of TFPI, Lp(a), and oxidized LDL antibody levels in patients with coronary artery disease.冠心病患者中组织因子途径抑制物(TFPI)、脂蛋白(a)[Lp(a)]及氧化型低密度脂蛋白抗体水平之间的关系。
Clin Biochem. 2005 Jan;38(1):92-6. doi: 10.1016/j.clinbiochem.2004.09.011.
7
Plasma and platelet plasminogen activator inhibitor-1 in patients with acute myocardial infarction.急性心肌梗死患者血浆及血小板中的纤溶酶原激活物抑制剂-1
Jpn Circ J. 2000 Aug;64(8):547-53. doi: 10.1253/jcj.64.547.
8
Tissue factor pathway inhibitor, natural coagulation inhibitors and hemostatic activation markers in patients with acute coronary syndromes.急性冠状动脉综合征患者的组织因子途径抑制剂、天然凝血抑制剂及止血激活标志物
Saudi Med J. 2005 Jun;26(6):937-42.
9
Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias.血脂异常中,凝血因子VIIc水平与组织因子途径抑制物降低及纤溶酶原激活物抑制物-1升高相关。
Arterioscler Thromb Vasc Biol. 1996 Jan;16(1):77-81. doi: 10.1161/01.atv.16.1.77.
10
Plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1 are correlated with the presence of transplant coronary artery disease in cardiac transplant recipients.心脏移植受者血浆组织型纤溶酶原激活物和纤溶酶原激活物抑制剂-1水平与移植冠状动脉疾病的存在相关。
Am J Cardiol. 1997 Jul 15;80(2):145-9. doi: 10.1016/s0002-9149(97)00308-1.

引用本文的文献

1
Biomarkers in coronary artery disease: systematic review and meta-analysis.冠状动脉疾病中的生物标志物:系统评价与荟萃分析。
Future Cardiol. 2025 Jan;21(1):39-46. doi: 10.1080/14796678.2024.2442214. Epub 2025 Jan 15.

本文引用的文献

1
Tissue Factor, Tissue Factor Pathway Inhibitor and Factor VII Activity in Cardiovascular Complicated Type 2 Diabetes Mellitus.心血管并发症型2型糖尿病中的组织因子、组织因子途径抑制物及凝血因子VII活性
Oman Med J. 2010 Jul;25(3):173-8. doi: 10.5001/omj.2010.52.
2
Tissue factor in cardiovascular disease pathophysiology and pharmacological intervention.组织因子在心血管疾病病理生理学及药物干预中的作用
Adv Pharmacol. 2010;59:259-92. doi: 10.1016/S1054-3589(10)59009-4.
3
Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction.急性冠脉综合征患者内源性溶栓功能受损可预测心血管死亡和非致死性心肌梗死。
J Am Coll Cardiol. 2010 May 11;55(19):2107-15. doi: 10.1016/j.jacc.2010.01.033.
4
Tissue factor: beyond coagulation in the cardiovascular system.组织因子:心血管系统中凝血之外的作用
Clin Sci (Lond). 2009 Oct 26;118(3):159-72. doi: 10.1042/CS20080622.
5
Lipoproteina(a) is a feature of the presence, diffuseness, and severity of coronary artery disease in Saudi population.脂蛋白(a)是沙特人群冠状动脉疾病的存在、弥漫程度及严重程度的一个特征。
Saudi Med J. 2009 Mar;30(3):346-52.
6
Relation of thrombomodulin, TFPI and plasma antioxidants in healthy individuals and patients with coronary heart disease.健康个体及冠心病患者中血栓调节蛋白、组织因子途径抑制物与血浆抗氧化剂的关系。
Acta Cardiol. 2008 Jun;63(3):341-6. doi: 10.2143/AC.63.3.1020311.
7
A comparison of the associations between seven hemostatic or inflammatory variables and coronary heart disease.七种止血或炎症变量与冠心病之间关联的比较。
J Thromb Haemost. 2007 Sep;5(9):1795-800. doi: 10.1111/j.1538-7836.2007.02677.x.
8
Tissue factor and tissue factor pathway inhibitor levels in coronary artery disease: correlation with the severity of atheromatosis.
Thromb Res. 2007;121(2):283-7. doi: 10.1016/j.thromres.2007.04.013. Epub 2007 Jun 20.
9
Tissue factor pathway inhibitor is highly susceptible to chymase-mediated proteolysis.组织因子途径抑制物对糜酶介导的蛋白水解作用高度敏感。
FEBS J. 2007 Jun;274(12):3065-77. doi: 10.1111/j.1742-4658.2007.05833.x. Epub 2007 May 17.
10
Soluble tissue factor and tissue factor pathway inhibitor in cardiovascular disease.
J Thromb Haemost. 2007 Mar;5(3):472-4. doi: 10.1111/j.1538-7836.2007.02402.x.

沙特人群中血管造影确诊的冠状动脉疾病患者的血浆组织因子途径抑制物水平

Plasma tissue factor pathway inhibitor levels in angiographically defined coronary artery disease among saudis.

作者信息

Habib Syed Shahid

机构信息

Associate Professor, Department of Physiology (29), College of Medicine, PO Box 2925, King Saud University, Riyadh 11461, Kingdom of Saudi Arabia.

出版信息

Oman Med J. 2013 May;28(3):191-4. doi: 10.5001/omj.2013.52.

DOI:10.5001/omj.2013.52
PMID:23772285
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3679606/
Abstract

OBJECTIVES

This study was aimed to determine plasma levels of total (TFPI-T) and free (TFPI-F) tissue factor pathway inhibitor, plasminogen activator inhibitor-1 (PAI-1), and tissue plasminogen activator (t-PA) in a cohort of Saudi patients with chronic stable angiographically defined coronary artery disease (CAD) and to determine its correlation with its severity.

METHODS

This cross sectional study was conducted in the department of physiology and department of cardiology, College of Medicine, and King Khalid University Hospital and King Saud University, Riyadh. Sixty known cases of CAD who had undergone angiography (35 males and 25 females) were selected. A control group included 39 (20 males and 19 females) healthy subjects. Fasting venous blood samples were analyzed for total (TFPI-T) and free (TFPI-F) tissue factor pathway inhibitor, plasminogen activator inhibitor-1 (PAI-1), and tissue plasminogen activator (t-PA). Gensini scores and vessel scores were determined for assessing CAD severity.

RESULTS

There were non-significant differences between age, body mass index (BMI) and Blood pressure between the controls and CAD subjects. A comparison of hemostatic markers between control and CAD patients showed significantly higher levels of Fibrinogen, PAI-1, TFPI-T and TFPI-F in CAD patients compared to control subjects. But there was no difference in plasma t-PA levels. TFPI-T had a significant positive correlation with severity of disease determined by Gensini Scores (r=0.344; p=0.006) and vessel scores (r=0.338; p=0.015).

CONCLUSION

Plasma levels of total tissue factor pathway inhibitor are significantly related with the presence and severity of CAD. Elevated levels of TFPI-T may be considered as useful diagnostic and prognostic markers in patients with CAD.

摘要

目的

本研究旨在测定一组经血管造影确诊为慢性稳定型冠心病(CAD)的沙特患者血浆中总组织因子途径抑制物(TFPI-T)、游离组织因子途径抑制物(TFPI-F)、纤溶酶原激活物抑制剂-1(PAI-1)和组织型纤溶酶原激活物(t-PA)的水平,并确定其与疾病严重程度的相关性。

方法

本横断面研究在利雅得国王哈立德大学医院和沙特国王大学医学院生理学系和心脏病学系进行。选取60例已接受血管造影的已知CAD病例(35例男性和25例女性)。对照组包括39名(20例男性和19例女性)健康受试者。对空腹静脉血样本进行总组织因子途径抑制物(TFPI-T)、游离组织因子途径抑制物(TFPI-F)、纤溶酶原激活物抑制剂-1(PAI-1)和组织型纤溶酶原激活物(t-PA)分析。测定Gensini评分和血管评分以评估CAD严重程度。

结果

对照组和CAD受试者在年龄、体重指数(BMI)和血压方面无显著差异。对照组与CAD患者止血标志物的比较显示,CAD患者的纤维蛋白原、PAI-1、TFPI-T和TFPI-F水平显著高于对照组。但血浆t-PA水平无差异。TFPI-T与Gensini评分(r = 0.344;p = 0.006)和血管评分(r = 0.338;p = 0.015)所确定的疾病严重程度呈显著正相关。

结论

血浆总组织因子途径抑制物水平与CAD的存在和严重程度显著相关。TFPI-T水平升高可被视为CAD患者有用的诊断和预后标志物。